Edwards Lifesciences Share Holder Equity 2010-2022 | EW
Edwards Lifesciences share holder equity from 2010 to 2022. Share holder equity can be defined as the sum of preferred and common equity items
- Edwards Lifesciences share holder equity for the quarter ending December 31, 2022 was $5.807B, a 0.5% decline year-over-year.
- Edwards Lifesciences share holder equity for 2022 was $5.807B, a 0.5% decline from 2021.
- Edwards Lifesciences share holder equity for 2021 was $5.836B, a 27.58% increase from 2020.
- Edwards Lifesciences share holder equity for 2020 was $4.574B, a 10.27% increase from 2019.
Edwards Lifesciences Annual Share Holder Equity (Millions of US $) |
2022 |
$5,807 |
2021 |
$5,836 |
2020 |
$4,574 |
2019 |
$4,148 |
2018 |
$3,140 |
2017 |
$2,956 |
2016 |
$2,619 |
2015 |
$2,503 |
2014 |
$2,191 |
2013 |
$1,544 |
2012 |
$1,479 |
2011 |
$1,338 |
2010 |
$1,308 |
2009 |
$1,158 |
Edwards Lifesciences Quarterly Share Holder Equity (Millions of US $) |
2022-12-31 |
$5,807 |
2022-09-30 |
$6,218 |
2022-06-30 |
$5,944 |
2022-03-31 |
$5,845 |
2021-12-31 |
$5,836 |
2021-09-30 |
$5,541 |
2021-06-30 |
$5,133 |
2021-03-31 |
$4,658 |
2020-12-31 |
$4,574 |
2020-09-30 |
$4,210 |
2020-06-30 |
$3,839 |
2020-03-31 |
$3,901 |
2019-12-31 |
$4,148 |
2019-09-30 |
$3,815 |
2019-06-30 |
$3,500 |
2019-03-31 |
$3,448 |
2018-12-31 |
$3,140 |
2018-09-30 |
$3,361 |
2018-06-30 |
$3,164 |
2018-03-31 |
$3,246 |
2017-12-31 |
$2,956 |
2017-09-30 |
$3,163 |
2017-06-30 |
$2,940 |
2017-03-31 |
$2,743 |
2016-12-31 |
$2,619 |
2016-09-30 |
$2,692 |
2016-06-30 |
$2,471 |
2016-03-31 |
$2,299 |
2015-12-31 |
$2,503 |
2015-09-30 |
$2,421 |
2015-06-30 |
$2,289 |
2015-03-31 |
$2,214 |
2014-12-31 |
$2,191 |
2014-09-30 |
$2,043 |
2014-06-30 |
$1,915 |
2014-03-31 |
$1,341 |
2013-12-31 |
$1,544 |
2013-09-30 |
$1,437 |
2013-06-30 |
$1,580 |
2013-03-31 |
$1,592 |
2012-12-31 |
$1,479 |
2012-09-30 |
$1,536 |
2012-06-30 |
$1,435 |
2012-03-31 |
$1,390 |
2011-12-31 |
$1,338 |
2011-09-30 |
$1,355 |
2011-06-30 |
$1,385 |
2011-03-31 |
$1,358 |
2010-12-31 |
$1,308 |
2010-09-30 |
$1,234 |
2010-06-30 |
$1,118 |
2010-03-31 |
$1,152 |
2009-12-31 |
$1,158 |
2009-09-30 |
$1,090 |
2009-06-30 |
$1,003 |
2009-03-31 |
$943 |
Sector |
Industry |
Market Cap |
Revenue |
Medical |
Medical Instruments Manufacturing |
$49.143B |
$5.382B |
Edwards Lifesciences Corporation deals in products and technologies aimed at treating advanced cardiovascular diseases, especially structural heart disease in critically ill patients. The company is the world's leading manufacturer of tissue heart valves and repair products used to replace or repair a patient's diseased or defective heart valve. Edwards is also a leading player in hemodynamic monitoring systems used to measure a patient's cardiovascular function in the hospital setting. The company's products and technologies are categorized into four main areas: Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), Surgical Structural Heart, and Critical Care.
|